(Q39455318)

12 September 2017

1 reference

title

Mitoxantrone. A review of its pharmacology and clinical efficacy in the management of hormone-resistant advanced prostate cancer (English)

1 reference

12 September 2017

1 reference

1 reference

Wiseman LR

1

1 reference

12 September 2017

Spencer CM

series ordinal

2

1 reference

12 September 2017

publication date

1 June 1997

1 reference

12 September 2017

1 reference

12 September 2017

volume

10

1 reference

12 September 2017

issue

6

1 reference

12 September 2017

page(s)

473-485

1 reference

Therapy of hormone refractory prostate carcinoma with mitoxantrone. A clinical phase II study

12 September 2017

cites work

1 reference

12 December 2020

Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer.

1 reference

12 December 2020

Assessment of quality of life in patients with prostate cancer

1 reference

12 December 2020

New aspects on the pharmacokinetics of mitoxantrone and its two major metabolites

1 reference

12 December 2020

Pharmacological disposition of 1,4-dihydroxy-5-8-bis[[2 [(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione dihydrochloride in the dog.

1 reference

12 December 2020

Inhibition of microtubule assembly is a possible mechanism of action of mitoxantrone

1 reference

12 December 2020

Mitoxantrone: a review of its pharmacological properties and use in acute nonlymphoblastic leukaemia

1 reference

12 December 2020

Combination of a long-acting delivery system for luteinizing hormone-releasing hormone agonist with Novantrone chemotherapy: increased efficacy in the rat prostate cancer model.

1 reference

12 December 2020

Mitoxantrone: modest activity in a phase II trial in advanced prostate cancer

1 reference

12 December 2020

Phase II study of platinum and mitoxantrone in metastatic prostate cancer: a Southwest Oncology Group Study

1 reference

12 December 2020

Identification of human urinary mitoxantrone metabolites

1 reference

12 December 2020

Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate

1 reference

12 December 2020

Clinical safety and tolerance of mitoxantrone

1 reference

12 December 2020

Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer

1 reference

12 December 2020

Non-hormone chemotherapy for prostate cancer: principles of treatment and application to the testing of new drugs.

1 reference

12 December 2020

14-Day continuous infusion of mitoxantrone in hormone-refractory metastatic adenocarcinoma of the prostate

1 reference

12 December 2020

Chemotherapy programs of the National Prostatic Cancer Project (NPCP).

1 reference

12 December 2020

The clinical pharmacology of mitozantrone

1 reference

12 December 2020

Pharmacokinetics and metabolism of mitoxantrone. A review

1 reference

12 December 2020

Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer

1 reference

12 December 2020

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

12 December 2020

Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer

1 reference

12 December 2020

Mitoxantrone for the treatment of advanced breast cancer: single-agent therapy in previously untreated patients.

1 reference

12 December 2020

Mitoxantrone as second-line single agent in metastatic breast cancer

1 reference

12 December 2020

1 reference

12 December 2020

Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer

1 reference

12 December 2020

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer

1 reference

12 December 2020

Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response

1 reference

12 December 2020

Human autopsy tissue concentrations of mitoxantrone.

1 reference

12 December 2020

Oral cyclophosphamide for the management of hormone-refractory prostate cancer

1 reference

12 December 2020

The McGill Pain Questionnaire: Major properties and scoring methods

1 reference

12 December 2020

Pharmacology of mitoxantrone in cancer patients

1 reference

12 December 2020

Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study

1 reference

12 December 2020

Cancer statistics, 1996.

1 reference

12 December 2020

Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer.

1 reference

12 December 2020

Inhibitory Effect of Mitoxantrone on Activity of Protein Kinase C and Growth of HL60 Cells1

1 reference

12 December 2020

Current chemotherapy and future directions in research for the treatment of advanced hormone-refractory prostate cancer

1 reference

12 December 2020

Rationale for the use of mitoxantrone in the older patient: cardiac toxicity.

1 reference

12 December 2020

Cardiotoxicity in patients treated with mitoxantrone: Southwest Oncology Group phase II studies.

1 reference

12 December 2020

1-beta-D-arabinofuranosylcytosine-, mitoxantrone-, and paclitaxel-induced apoptosis in HL-60 cells: improved method for detection of internucleosomal DNA fragmentation.

1 reference

12 December 2020

Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer

1 reference

12 December 2020

10.2165/00002512-199710060-00007

Identifiers

DOI

1 reference

Dimensions Publication ID

12 September 2017

1039783889

0 references

1 reference